ERBB2 and neoplasm: In patients with sHR positive/HER2 negative tumours (n = 618), we observed an absolute increase of 6% in the proportion of patients with a low uPA/PAI-1 status compared with the entire cohort (44% vs. 38%, respectively), with a still notably low risk of recurrence (7 of 271; HR 2.74).